Sari Alon

447 total citations
25 papers, 209 citations indexed

About

Sari Alon is a scholar working on Physiology, Organic Chemistry and Molecular Biology. According to data from OpenAlex, Sari Alon has authored 25 papers receiving a total of 209 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Physiology, 12 papers in Organic Chemistry and 6 papers in Molecular Biology. Recurrent topics in Sari Alon's work include Lysosomal Storage Disorders Research (17 papers), Carbohydrate Chemistry and Synthesis (12 papers) and Trypanosoma species research and implications (5 papers). Sari Alon is often cited by papers focused on Lysosomal Storage Disorders Research (17 papers), Carbohydrate Chemistry and Synthesis (12 papers) and Trypanosoma species research and implications (5 papers). Sari Alon collaborates with scholars based in United States, United Kingdom and Spain. Sari Alon's co-authors include Raul Chertkoff, Einat Almon, Pilar Giraldo, Yoram Tekoah, Pauline M. Rudd, Bonita Rup, Derralynn Hughes, Yoseph Shaaltiel, Einat Brill‐Almon and Yaron Ilan and has published in prestigious journals such as Gastroenterology, PLoS ONE and Toxicology and Applied Pharmacology.

In The Last Decade

Sari Alon

24 papers receiving 205 citations

Peers

Countries citing papers authored by Sari Alon

Since Specialization

Citations

This map shows the geographic impact of Sari Alon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sari Alon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sari Alon more than expected).

Fields of papers citing papers by Sari Alon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sari Alon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sari Alon. The network helps show where Sari Alon may publish in the future.

Co-authorship network of co-authors of Sari Alon

This figure shows the co-authorship network connecting the top 25 collaborators of Sari Alon. A scholar is included among the top collaborators of Sari Alon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sari Alon. Sari Alon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phase III, open‐label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies 2024 ·Journal of Inherited Metabolic Disease ·Myrl Holida, Aleš Linhart, Antonio Pisani, Nicola Longo, François Eyskens, Özlem Göker-Alpan, Eric Wallace, Patrick Deegan, Camilla Tøndel, Ulla Feldt‐Rasmussen, Derralynn Hughes, (unknown), (unknown), Einat Almon, Sari Alon, Raul Chertkoff, David G. Warnock, Stephen Waldek, William R. Wilcox, John Bernat	6
2	Assessment of immunogenicity from the pegunigalsidase alfa clinical trial program: Integrated analysis of de novo and treatment-boosted anti-drug antibodies 2024 ·Molecular Genetics and Metabolism ·John Bernat, Derralynn Hughes, Aleš Linhart, Robert J. Hopkin, Camilla Tøndel, David G. Warnock, Bonita Rup, Irene Koulinska, Rossana Rocco, Sari Alon, Raul Chertkoff, Einat Almon, (unknown), Eric Wallace	1
3	Tolerability of pegunigalsidase alfa across the clinical program: Integrated analysis of infusion-related reactions by dosing regimens 2024 ·Molecular Genetics and Metabolism ·Derralynn Hughes, John Bernat, Aleš Linhart, Nicola Longo, Ankit Mehta, Camilla Tøndel, Bojan Vujkovac, (unknown), Irene Koulinska, Raul Chertkoff, Sari Alon, (unknown), Eric Wallace	1
4	Long-term safety and efficacy of pegunigalsidase alfa: A multicenter 6-year study in adult patients with Fabry disease 2023 ·Genetics in Medicine ·Derralynn Hughes, Derlis Gonzalez, Gustavo Maegawa, John Bernat, Myrl Holida, Pilar Giraldo, Mohamed G. Atta, Raul Chertkoff, Sari Alon, Einat Almon, Rossana Rocco, Özlem Göker-Alpan	20
5	Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study 2023 ·Orphanet Journal of Rare Diseases ·Aleš Linhart, Gabriela Dostálová, Kathy Nicholls, Michael L. West, Camilla Tøndel, Ana Jovanović, Pilar Giraldo, Bojan Vujkovac, Tarekegn Geberhiwot, Einat Brill‐Almon, Sari Alon, Raul Chertkoff, (unknown), Derralynn Hughes	24
6	Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in patients with Fabry disease: Two-year interim results from the ongoing phase 3 BRIGHT51 open-label extension study 2023 ·Molecular Genetics and Metabolism ·John Bernat, Myrl Holida, Nicola Longo, Özlem Göker-Alpan, Eric Wallace, Patrick Deegan, Camilla Tøndel, François Eyskens, Ulla Feldt‐Rasmussen, Derralynn Hughes, Antonio Pisani, Rossana Rocco, Einat Almon, Sari Alon, Raul Chertkoff, David G. Warnock, Stephen Waldek, William R. Wilcox	2
7	Switching from agalsidase alfa to pegunigalsidase alfa to treat patients with Fabry disease: 1 year of treatment data from BRIDGE, a phase 3 open-label study 2021 ·Molecular Genetics and Metabolism ·Aleš Linhart, Gabriela Dostálová, Kathy Nicholls, Michael L. West, Camilla Tøndel, Ana Jovanović, Pilar Giraldo, Bojan Vujkovac, Tarekegn Hiwot, Einat Almon, Sari Alon, (unknown), Raul Chertkoff, Derralynn Hughes	1
8	Novel Orally Administered Recombinant Anti-TNF Alpha Fusion Protein for the Treatment of Ulcerative Colitis 2020 ·Journal of Clinical Gastroenterology ·Einat Almon, Yoseph Shaaltiel, Wisam Sbeit, Alex Fich, Doron Schwartz, (unknown), (unknown), (unknown), (unknown), Sari Alon, Raul Chertkoff, Alona Paz, Yaron Ilan	17
9	Pegunigalsidase alfa for the treatment of Fabry disease: Preliminary results from a phase III open label, switch over study from agalsidase alfa 2019 ·Molecular Genetics and Metabolism ·Aleš Linhart, Kathy Nicholls, Michael L. West, Camilla Tøndel, Ana Jovanović, Pilar Giraldo, Bojan Vujkovac, Einat Almon, Sari Alon, (unknown), (unknown), Raul Chertkoff, Derralynn Hughes	4
10	FP805PROGRESSION OF NEPHROPATHY IN FABRY PATIENTS RECEIVING ENZYME REPLACEMENT THERAPY (ERT); RELATION TO ANTI-DRUG ANTIBODY (ADA) STATUS AND PROTEINURIA 2018 ·Nephrology Dialysis Transplantation ·David G. Warnock, Sari Alon, Raul Chertkoff, Einat Brill‐Almon	1
11	Pegunigalsidase alfa, a novel PEGylated ERT for Fabry disease: Two-year safety and efficacy follow up 2018 ·Molecular Genetics and Metabolism ·Derralynn Hughes, Pilar Giraldo, Myrl Holida, Özlem Göker-Alpan, Gustavo Maegawa, Raphael Schiffmann, Sari Alon, (unknown), (unknown), Einat Brill‐Almon, Raul Chertkoff	2
12	739 - A Novel Orally Administered Recombinant Anti-TNF Alpha Fusion Protein for the Treatment of Mild to Moderate Ulcerative Colitis: Results of a Phase 2A Clinical Trial Showing Promising Results 2018 ·Gastroenterology ·Einat Almon, Eran Goldin, Wisam Sbeit, Eran Israeli, (unknown), Ofer Ben‐Bassat, Matti Waterman, Nikola Milinić, (unknown), (unknown), (unknown), (unknown), Sari Alon, Raul Chertkoff, Alona Paz, Yaron Ilan	1
13	Enhanced pharmacokinetics profile of pegunigalsidase alfa (PRX-102) supports once-monthly 2mg/kg dosing for the treatment of Fabry disease 2018 ·Molecular Genetics and Metabolism ·David G. Warnock, (unknown), Derralynn Hughes, Raphael Schiffmann, Sari Alon, Raul Chertkoff, Einat Brill‐Almon	1
14	Immunogenicity of glycans on biotherapeutic drugs produced in plant expression systems—The taliglucerase alfa story 2017 ·PLoS ONE ·Bonita Rup, Sari Alon, (unknown), Einat Almon, Raul Chertkoff, Yoram Tekoah, Pauline M. Rudd	39
15	An oral administration of a recombinant anti-TNF fusion protein is biologically active in the gut promoting regulatory T cells: Results of a phase I clinical trial using a novel oral anti-TNF alpha-based therapy 2017 ·Journal of Immunological Methods ·Einat Almon, Tawfik Khoury, (unknown), Svetlana Gingis‐Velitski, Sari Alon, Raul Chertkoff, (unknown), Yoseph Shaaltiel, Yaron Ilan	20
16	PRX-102 for treating Fabry disease: immunogenicity and PK results from a phase 1-2 study 2017 ·Molecular Genetics and Metabolism ·David G. Warnock, Derralynn Hughes, (unknown), Pilar Giraldo, Derlis Gonzalez, Myrl Holida, Özlem Göker-Alpan, Gustavo Maegawa, Mohamed G. Atta, Kathy Nicholls, Raphael Schiffmann, Ahmad Tuffaha, (unknown), Raul Chertkoff, Sari Alon, Einat Brill‐Almon	2
17	Long-term efficacy and safety results of taliglucerase alfa through 5 years in adult treatment-naïve patients with Gaucher disease 2016 ·Blood Cells Molecules and Diseases ·Ari Zimran, (unknown), Pilar Giraldo, Hanna Rosenbaum, Fiorina Giona, Мilan Petakov, (unknown), Sergio Solorio, Peter A. Cooper, (unknown), Sari Alon, Raul Chertkoff	22
18	Novel treatment for Fabry disease: IV administration of plant derived alpha-gal-A enzyme safety and efficacy interim report 2016 ·Molecular Genetics and Metabolism ·Derralynn Hughes, (unknown), Pilar Giraldo, Derlis Gonzalez, Myrl Holida, Özlem Göker-Alpan, (unknown), Mohamed G. Atta, Kathy Nicholls, Raphael Schiffmann, Ahmad Tuffaha, Jeannie Visootsak, Laura Barisoni, Robert B. Colvin, (unknown), Sari Alon, (unknown), (unknown), Einat Brill‐Almon, Raul Chertkoff	1
19	Pharmacokinetics of Novel Plant Cell-Expressed Taliglucerase Alfa in Adult and Pediatric Patients with Gaucher Disease 2015 ·PLoS ONE ·Richat Abbas, Glen Park, Bharat Damle, Raul Chertkoff, Sari Alon	9
20	Preclinical and first-in-human evaluation of PRX-105, a PEGylated, plant-derived, recombinant human acetylcholinesterase-R 2015 ·Toxicology and Applied Pharmacology ·Jacob Atsmon, Einat Brill‐Almon, (unknown), Raul Chertkoff, Sari Alon, (unknown), (unknown), (unknown), Daniel Bartfeld, Avidor Shulman, (unknown), Tehila Ben-Moshe, (unknown), Hermona Soreq, Yoseph Shaaltiel	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact